PharmaSGP publishes preliminary half-year figures for 2025 Gräfelfing, September 11, 2025 – The German OTC pharmaceutical company PharmaSGP Holding SE generated revenues of €66.0 million in the first half of 2025 based on preliminary, unaudited figures. This corresponds to a 13.0% increase in revenues compared to the previous year (€58.4 million) [ … ]

PharmaSGP Holding SE publishes joint reasoned statement of the Management Board and Supervisory Board on the public delisting tender offer by FUTRUE GmbH Gräfelfing, July 28, 2025 – The Management Board and Supervisory Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5, WKN: A2P4LJ) today published their joint reasoned statement pursuant to Sectio [ … ]

PharmaSGP Holding SE: Acceptance period for FUTRUE GmbH’s public delisting tender offer underway Gräfelfing, July 18, 2025 – PharmaSGP Holding SE (ISIN: DE000A2P4LJ5 WKN: A2P4LJ) announces that the public delisting tender offer made by FUTRUE GmbH to the shareholders of PharmaSGP is open for acceptance. Shareholders of PharmaSGP can tender their [ … ]

PharmaSGP Holding SE holds 2025 Annual General Meeting  91.12% of the registered share capital was represented Minimum dividend of €0.05 per dividend-bearing share resolved Management Board reports on successful operational development in 2024; forecast for current fiscal year 2025 confirmed Gräfelfing, June 26, 2025 – German OTC pharmaceutical  [ … ]

PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met Gräfelfing, June 18, 2025 – PharmaSGP SE (ISIN: DE000A2P4LJ5) currently holds treasury shares representing approximately 4.06% of its share capital as a result of last year's share buyback. In order to make optimal use of the new authorization to acqu [ … ]

PharmaSGP continues its growth course in 2025 Gräfelfing, May 15, 2025 – The German OTC pharmaceutical company PharmaSGP Holding SE has made a successful start to 2025, achieving a 10.8% increase in revenues to €33.5 million in the first quarter based on preliminary, unaudited figures (prior-year quarter: €30.2 million). Compared to the previous y [ … ]

PharmaSGP with significant increase in revenues and EBITDA in 2024 Gräfelfing, April 15, 2025 – Based on preliminary, unaudited figures, the German OTC pharmaceutical company PharmaSGP Holding SE significantly increased its revenues from 2023 by 17.5% to € 118.8 million in the 2024 financial year. The sole driver of the positive business developme [ … ]